Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...

A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...

Ebglyss provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients...

Ebglyss provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients...

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS...

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS...